← ANALYST RATINGS · TIPRANKS
Odyssey Therapeutics, Inc. (ODTX): analyst forecast and price target
Analyst consensus
Strong Buy3 Buy0 Hold0 Sell
Ratings of 3 analysts in the last 3 months · top analysts only12-month forecast
Based on 3 price targets given in the last 3 months, the average target is $29.50, the highest $30.00, the lowest $29.00. The average is +71.8% from the last price of $17.17.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Name not given | — | $27.00 | Buy | +57.3% | Initiated | 11.10.26on TipRanks Oct 12 05:30 | −3.8%next day −5.6% | ↗ |
| Name not given | — | $42.00 | Buy | +144.6% | Initiated | 08.10.26on TipRanks Oct 11 09:55 | +0.6%next day +4.3% · 5 days −2.8% | ↗ |
| Emily Bodnar★★★★★★★★★★#2140 · hits 39% · avg +7.2% | H.C. Wainwright | $44.00 | Buy | +156.3% | Reiterated | 21.09.26on TipRanks 13:55 | −7.0%next day +1.2% · 5 days −5.9% | ↗ |
| Tyler Van Buren★★★★★★★★★★#42 · hits 64% · avg +38.8% | TD Cowen | — | Buy | — | Reiterated | 11.08.26on TipRanks Aug 12 02:40 | −7.9%next day +5.8% · 5 days +8.3% | ↗ |
| Brian Cheng★★★★★★★★★★#1122 · hits 55% · avg +14.0% | J.P. Morgan | $26.00 → $29.00+11.5% | Buy | +68.9% | Reiterated | 10.08.26on TipRanks Aug 11 08:07 | +4.8%next day −7.9% · 5 days −5.9% | ↗ |
| David Nierengarten★★★★★★★★★★#297 · hits 55% · avg +23.0% | Wedbush | $30.00 | Buy | +74.7% | Reiterated | 05.08.26on TipRanks Aug 6 05:50 | +4.9%next day +3.3% · 5 days +3.0% | ↗ |
| Jeff Jones★★★★★★★★★★#749 · hits 46% · avg +20.3% | Oppenheimer | $40.00 | Buy | +133.0% | Reiterated | 18.06.26on TipRanks 08:10 | +2.2%next day −1.5% · 5 days −2.9% | ↗ |
| Eric Schmidt FCA★★★★★★★★★★#358 · hits 51% · avg +84.1% | Cantor Fitzgerald | — | Buy | — | Initiated | 02.06.26on TipRanks 06:10 | −0.3%next day −0.7% · 5 days +3.9% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Odyssey Therapeutics, Inc.
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $34.33 at a price of $22.22 (+54.5%); now: $34.40 at $17.17 (+100.3%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 5 | 5 | 5 | 0 | 0 |
| Buy | 0 | 3 | 3 | 6 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Best top-analyst consensus in the sector · Healthcare
About Odyssey Therapeutics, Inc.
- CEO: Gary D. Glick
- Employees: 100
- 51 Sleeper Street, Boston, MA, 02210, US
- odysseytx.com
Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering and developing novel treatments for autoimmune and inflammatory diseases. Its diverse pipeline features several key drug candidates: OD-001, an oral small molecule that inhibits receptor-interacting protein kinase 2, which is currently in Phase 2a clinical trials for ulcerative colitis. Also included is OD-002, an oral small molecule SLC15A4 inhibitor engineered to prevent harmful inflammatory responses driven by TLR7/8/9-mediated activation of interferon regulatory factor 5 (IRF5). Another program, OD-003, is a protein therapeutic designed to selectively agonize tumor necrosis factor receptor 2 on T regulatory cells. Further assets in its portfolio comprise a bispecific antagonist targeting TSLP and IL-33, an oral small molecule functioning as an interleukin-1 receptor-associated kinase 4 scaffolding inhibitor, and a separate small molecule inhibitor specifically targeting IRF5. The company was founded in 2021 and is headquartered in Boston, Massachusetts.
Data from the stock’s TipRanks forecast page, read 15 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗